Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Open Label Pilot Study of CUV1647 Implant in Solar Urticaria
2007-001068-55Phase 2Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Feb 2008
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Afamelanotide in solar urticaria (SU), sponsored by Clinuvel Pharmaceuticals. Primary endpoint: Minimum urticarial dose at Day 30 vs baseline. Started Feb 2008; status: completed.
02
Drugs
Afamelanotide
03
Conditions
solar urticaria (SU)
Beyond the preview
Go deeper on 2007-001068-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001068-55.